Table 2.

Differences in MSLT outcomes.

Variable	Not Using a REMS-AD at Assessment (n = 324)	REMS-AD Continued at MSLT (n = 53)	REMS-AD Tapered Prior to MSLT (n = 121)
Mean sleep latency, minutes	10.21 ± 0.28	9.20 ± 0.70	8.78 ± 0.46*
Mean number of SOREMs	0.36 ± 0.06	0.13 ± 0.15	0.65 ± 0.10#
Patients with ≥2 SOREMs, n (%)	31 (9.57)	1 (1.89)	23 (19.1)#
Patients meeting criteria for narcolepsy, n (%)	19 (5.86)	1 (1.89)	16 (13.22)#

MSLT = multiple sleep latency testing; REMS-AD = rapid eye movement suppressing antidepressant; SOREM = sleep-onset rapid eye movement episode. *P value < .009 compared with mean sleep latency for patients not on a REMS-AD at assessment. ^#P value < .05 compared with mean number of SOREMS, % with ≥2 SOREMs, and % meeting criteria for narcolepsy (mean sleep latency ≤8 minutes and ≥2 SOREMs) on MSLT for patients not on a REMS-AD at assessment and those who continued on REMS-AD at the time of MSLT.